» Articles » PMID: 2862927

Selective Interaction of Novel Anxiolytics with 5-hydroxytryptamine1A Receptors

Overview
Journal Biol Psychiatry
Publisher Elsevier
Specialty Psychiatry
Date 1985 Sep 1
PMID 2862927
Citations 63
Authors
Affiliations
Soon will be listed here.
Abstract

Radioligand binding studies were used to analyze the interactions of two novel anxiolytics, buspirone and TVX Q 7821, with a series of 10 neuronal membrane receptor sites. Buspirone (IC50 = 24 nM) and TVX Q 7821 (IC50 = 9.5 nM) display the highest affinity for 5-hydroxytryptamine1A (5-HT1A) binding sites labeled by 3H-8-hydroxy-2-(di-n-pro-pylamino) tetralin (DPAT). By contrast, buspirone is 16-fold weaker at dopamine (D2) receptors (IC50 = 380 nM), whereas TVX Q 7821 is 6-fold less potent at alpha-adrenergic1 sites (IC50 = 58 nM). At the other receptors studied, buspirone and TVX Q 7821 had similar pharmacological profiles. Both agents display moderate affinity for histamine (H1), alpha-adrenergic2, and 5-HT2 binding sites. The drugs are essentially inactive at 5-HT1B, calcium channel antagonist, muscarinic cholinergic, and benzodiazepine receptors. These results suggest that the anxiolytic effects of buspirone and TVX Q 7821 may be mediated by central 5-HT1A receptors.

Citing Articles

Long-Term 5-HT Receptor Agonist NLX-112 Treatment Improves Functional Recovery After Spinal Cord Injury.

Lin C, Li K, Gitchell T, Lee Y Int J Mol Sci. 2025; 26(1.

PMID: 39796094 PMC: 11719485. DOI: 10.3390/ijms26010239.


Buspirone Dose-Response on Facilitating Forelimb Functional Recovery in Cervical Spinal Cord Injured Rats.

Ahmed R, Edgerton V, Li S, Zheng Y, Alam M Dose Response. 2021; 19(1):1559325821998136.

PMID: 33716591 PMC: 7924001. DOI: 10.1177/1559325821998136.


International Union of Basic and Clinical Pharmacology. CX. Classification of Receptors for 5-hydroxytryptamine; Pharmacology and Function.

Barnes N, Ahern G, Becamel C, Bockaert J, Camilleri M, Chaumont-Dubel S Pharmacol Rev. 2020; 73(1):310-520.

PMID: 33370241 PMC: 7770494. DOI: 10.1124/pr.118.015552.


Discovery of Novel pERK1/2- or β-Arrestin-Preferring 5-HT Receptor-Biased Agonists: Diversified Therapeutic-like versus Side Effect Profile.

Sniecikowska J, Gluch-Lutwin M, Bucki A, Wieckowska A, Siwek A, Jastrzebska-Wiesek M J Med Chem. 2020; 63(19):10946-10971.

PMID: 32883072 PMC: 7586344. DOI: 10.1021/acs.jmedchem.0c00814.


The selective 5-HT receptor agonist, NLX-112, exerts anti-dyskinetic and anti-parkinsonian-like effects in MPTP-treated marmosets.

Fisher R, Hikima A, Morris R, Jackson M, Rose S, Varney M Neuropharmacology. 2020; 167:107997.

PMID: 32057799 PMC: 7103782. DOI: 10.1016/j.neuropharm.2020.107997.